Concepedia

Author

Holly Tovey

Institute of Cancer ResearchORCID

Also Known As

H Tovey, H. Tovey, Holly Tovey, Kilburn, L, Robertson, John F.R., TNT investigators, Tovey, H, Tovey, Holly

140

Publications

2.3K

Citations

14

H-Index

21

Concepts

All Affiliations

Institute of Cancer ResearchRoyal Marsden NHS Foundation TrustBreast Cancer NowRoyal Marsden HospitalKing's College London
HT

About

Holly Tovey is an author at Institute of Cancer Research specializing in cancer therapeutics, oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

1.1K

2

Pathology

6

6

1.1K

3

Cell Biology

2

2

875

4

Health Sciences

1

1

13

5

Gastroenterology

1

1

10

Holly Tovey

×

20

Publications

2.2K

Citations

14

H-Index

YearCitations

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Andrew Tutt, Holly Tovey, Maggie C.U. Cheang,

Nature Medicine

2018

862

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

Isaac García-Murillas, Neha Chopra, Iñaki Comino‐Méndez,

JAMA Oncology

2019

414

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

Neha Chopra, Holly Tovey, Alex Pearson,

Nature Communications

2020

252

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)

Andrew Tutt, Lucy Kilburn, Cheryl Gilett,

Cancer Research

2015

164

Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

Christina Guo, Adam Sharp, Bora Gürel,

Nature

2023

103

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Michael Kolinsky, Pasquale Rescigno, Diletta Bianchini,

Annals of Oncology

2020

85

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

R. Charles Coombes, Holly Tovey, Lucy Kilburn,

JAMA Oncology

2021

43

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Bristi Basu, Matthew Krebs, Raghav Sundar,

Annals of Oncology

2018

33

Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

Maxime Chénard-Poirier, Martin Kaiser, Kevin Boyd,

Journal of Clinical Oncology

2017

29

HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer

M.A. Bergamino, Elena López‐Knowles, Gabriele Morani,

EBioMedicine

2022

25

Page 1